Comments
The public issue of Gland Pharma to raise about ₹6,480 crore, including ₹1,250 crore fresh issue of shares, has been oversubscribed by 2.06 times on the last day on Wednesday, thanks to qualified institutional buyers.
According data available with stock exchanges, the QIB portion was subscribed by over 6 times. However, the IPO received a lukewarm response from retail investors (0.23 per cent) and high net worth individuals (0.50 per cent).
Ahead of the issue, the Hyderabad-based company, in which Chinese firm Fosun Pharma, is a major investor, had raised ₹1,943.86 crore from 70 anchor investors.
The IPO price band was fixed at ₹1,490-1,500 a share.
The company is an integrated manufacturer of complex, injectable products.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.